Geriatrics

Novo Nordisk has terminated the 1-year follow-up for the evoke and evoke+ trials after no significant reduction was indicated in either.

An audio recap of the top 5 stories in healthcare news from the week of 10/12-18.

Stay updated with the latest healthcare breakthroughs, including FDA updates and phase 3 trial readouts, in this week's essential news roundup.

Roche’s Elecsys pTau181 blood test helps primary care clinicians rule out Alzheimer’s amyloid pathology in patients with cognitive symptoms.

In a study, the prevalence of transthyretin cardiac amyloidosis reached 17% in Black men over 75 years old.

FDA approval of weekly subcutaneous lecanemab-irmb offers at-home maintenance therapy for early Alzheimer’s after initial intravenous treatment.

According to investigators, individuals with 3 or more risk factors for metabolic syndrome have a 40% greater risk of developing Parkinson’s.

A review estimated that eliminating cerebrovascular disease could have prevented 1.5 to 1.8 million US dementia cases in 2020.

A new study found older adults with insomnia experience significantly greater and longer-lasting depressive symptoms after inflammatory exposure.

Findings showed GLP-1 RAs reduced the risk of overall dementia, particularly Alzheimer’s disease and non-vascular dementias, compared with metformin.

Contrary to earlier research, a Framingham Heart Study analysis found no significant dementia risk tied to transient ischemic attack over 2 decades.

Disrupted circadian rest-activity rhythms were tied to faster biological aging in older adults, independent of age, sex, or race, new study shows.

New findings reveal that timing of antihypertensive medication—bedtime vs. morning—shows no significant impact on health outcomes for frail older adults.

Discover effective treatments for bunions in older adults, including advanced surgical options and minimally invasive techniques to enhance mobility and quality of life.

Advanced biological aging significantly associated with the dementia risk, a new study found.

New research reveals older adults face higher anaphylaxis risks from medications and IV contrast, often presenting with severe symptoms and outcomes.

Parkinson’s is often diagnosed after symptoms of the disease have already begun to appear; these results may lead to a more preemptive indication of pathogenesis.

New research links high smoke pollution to increased respiratory hospitalizations in older adults, highlighting urgent health risks from wildfires.

The FDA granted fast-track status to Biogen’s BIIB080, a tau-targeting therapy for Alzheimer Disease, which is now being evaluated in the global phase 2 CELIA study.

Our top 5 headlines included a new approval for atopic dermatitis, expert consensus on anaphylaxis care, and the end of the semaglutide shortage.

More than 90% of patients with hemophilia B eliminated factor IX prophylaxis 4 years after treatment with etranacogene dezaparvovec (HEMGENIX) gene therapy.

SGLT2 inhibitors lower the risk of MACE in older age, despite smaller HbA1c reductions, while GLP-1 RAs were more cardioprotective in younger individuals with T2D.

This Month in Review highlights the top psychiatry news in January.

A study indicated that telomere length may not directly cause age-related brain diseases, but healthier lifestyles could counteract the harmful effects of shorter telomeres.

A study showed that greater total cholesterol and low-density lipoprotein cholesterol were associated with a quicker decline in global cognition.